While evidence exists to support HER2 activity to be directly linked to enhanced mobility and invasiveness of cancer cells, data on the clinical relevance of the first discovered protein of the erbB family, the erbB1 receptor, is less conclusive5. Here, ERBB2 is linked to cancer.